Abstract： Objective： To observe the clinical efficacy of Yiqi Huoxue Huatan Decoction in treating stable coronary artery disease （CAD） and its impact on patients' quality of life. Methods：A total of 120 patients with stable CAD meeting the inclusion criteria were randomly divided into a control group and an observation group using the random number table method，with 60 cases in each group. The control group received standardized treatment for stable CAD， including antiplatelet aggregation drugs， statins， nitrates， β -blockers， and other medications. The observation group received Yiqi Huoxue Huatan Decoction in addition to the standardized western medical treatment of the control group. Changes in traditional Chinese medicine syndrome scores，36-Item Short Form Health Survey（ SF-36） scores， Seattle Angina Questionnaire （SAQ） scores， electrocardiogram （ECG） indices， triglyceride （TG）， total cholesterol （TC），high-density lipoprotein cholesterol （HDL-C），and low-density lipoprotein cholesterol （LDL-C） levels were observed before and after six weeks of treatment. Results：Finally，57 cases in the control group and 58 cases in the observation group were included for statistical analysis. After treatment， traditional Chinese medicine syndrome scores and nitroglycerin use frequency scores decreased in both groups compared to before treatment， with lower scores in the observation group than in the control group， showing significant differences （P＜0.05）. SF-36 scores and SAQ subscale scores increased in both groups compared to before treatment， with higher scores in the observation group than in the control group， showing significant differences （P＜0.05）. After treatment， TG， TC， and LDL-C levels decreased in both groups compared to before treatment， with lower levels in the observation group than in the control group，showing significant differences （P＜0.05）. No significant differences were found in HDL-C levels between the two groups before and after treatment， or between the two groups after treatment （P＞0.05）. After treatment， the total improvement rate of ST-T segment on ECG was 77.6% （45/58） in the observation group and 28.1% （16/57） in the control group， showing a significant difference （P＜0.01）. After treatment， the total clinical efficacy rate was 94.8%（ 55/58） in the observation group and 71.9%（ 41/57） in the control group，showing a significant difference （P＜0.05）. The incidence of major adverse cardiovascular events was significantly different between the two groups （χ2=4.950， P=0.026， P＜0.05）. Conclusion： Yiqi Huoxue Huatan Decoction combined with conventional western medical treatment can significantly reduce traditional Chinese medicine syndrome scores，improve SF-36 and SAQ scores，regulate lipid levels，thereby improving the quality of life in patients with stable CAD and reducing the incidence of adverse cardiovascular events.